Primary Total: $45,761,357
Total: $41,747,652
Primary Total: $37,707,624
Total: $1,178,780
*Implementation Grant: Preparing Physicians for the Future, (428289), Robert Wood Johnson Fdtn, $688,112.
*General Clinical Research Center, (428607), Research Resources, $490,668.
*General Clinical Research Center, Patient Care, (433016), Research Resources, $425,474.
*General Clinical Research Center - Clinical Associate Physician Peter Morris, MD, (433186), Research Resources, $57,023.
*General Clinical Research Center: Nurses and Dieticians Salaries, (433015), Research Resources, $141,407.
Total: $2,817,875
Primary Total: $1,735,526
*Eyelid Kinematics in Health and Disease, (428132), National Eye Institute, $116,886.
*Psychoneuroimmunology: Modulation of T-Cell Trafficking, (425522), National Institute of Mental Health, $101,574 (adjustment).
NGF-Antagonists as Possible Analesics, (428533), Genentech Inc, $12,500.
B.M.Davis/K.M.Albers/K.B.Seroogy
*Effects of Overexpression of NGF in Transgenic Mice, (426996), Neurological Communicative Disorders and Stroke, $177,618 (adjustment).
*Effects of Overexpression of NGF in Transgenic Mice, (432980), Neurological Communicative Disorders and Stroke, $23,840 (adjustment).
Neuroscience Research Experience for Undergraduates, (428820), National Science Fdtn, $50,000.
Analysis of the Anti-Parkinsonian Effects of GDNF in MPTP Intoxicated Rhesus Monkeys, (429075), AMGen, $325,872.
Dose Response to ICV-GDNF in Parkinsonian Rhesus Monkeys, (428571), AMGen, $107,418.
GDNF-Levodopa Interactions in Rhesus Monkeys, (429128), AMGen, $69,226.
Graft Evaluation in the Parkinsonian Brain (Core B: Primates), (427735), Univ of Rochester, $4,000 (adjustment).
*Impaired Metabolic Function and Neurodegeneration, (428639), Alzheimers Assoc, $29,370.
*Map 5, Sprouting, and Alzheimer's Disease Pathology, (425731), National Institute on Aging, $134,379 (adjustment).
Role of Opiate Drugs in Neural Development, (427650), National Institute on Drug Abuse, $137,631 (adjustment).
Central Natriuretic Peptide Systems and Stress Regulation: Functional/Anatomical Studies, (428216), American Heart Assoc KY Affiliate, $14,521.
Cellular Correlates of Axonal Sprouting, (428482), Montana State Univ, $21,946.
*Functional Anatomy of Limbic Neuroendocrine Circuits, (426571), National Institute of Mental Health, $109,775 (adjustment).
Role and Regulation of Galanin in Pituitary Adenomas, (426716), Arthritis Diabetes Digestive and Kidney Diseases, $102,700 (adjustment).
Identification and Characteristization of Brain GnRH Receptors, (427157), Child Health and Human Development, $167,444 (adjustment).
Mechanisms of Repair in Injured Oligodendrocytes, (428662), National Multiple Sclerosis Society, $73,323.
*Integration, Cellular Signals, Neuroarchitecture, (428981), Neurological Communicative Disorders and Stroke, $141,126.
*B-Amyloid and Neuronal Calcium Misregulation, (426169), Neurological Communicative Disorders and Stroke, $144,317 (adjustment).
*Calcium Signaling and Neuronal Degeneration, (428930), Neurological Communicative Disorders and Stroke, $74,326.
*Alzheimer's Disease Research Center: Project 1, (432781), National Institute on Aging, $15 (adjustment).
*Alzheimer's Disease Research Center: Project 1, (433088), National Institute on Aging, $124,963.
*AB, Free Radicals, Ion-Motive Atpases and Neuronal Death, (428269), Alzheimers Assoc, $100,000.
Cell and Molecular Diversity of Extraocular Muscle, (427189), National Eye Institute, $88,808 (adjustment).
*Human Age-Related Changes in Synaptic Density, (428711), National Institute on Aging, $155,305.
*Human Age-Related Changes in Synaptic Density, (433188), National Institute on Aging, $5,000.
Tyrosine Hydroxylase in Primary Somatosensory Neurons, (426911), National Science Fdtn, $5,000 (adjustment).
Fellowship for Suzanne Numan: Neurotrophins and Their Receptors in Ventral Midbrain, (428330), National Institute of Mental Health, $13,008.
*Characterization and Quantification of Grafted Cell Survival, (427728), Theracell Inc, $50,723 (adjustment).
*Prolactin and Bile Secretory Function, (427863), National Institute Diabetes & Digestive & Kidney, $169,240 (adjustment).
Estrogen Receptive Neurons: Synaptic Circuitry, (426016), Child Health and Human Development, $102,439 (adjustment).
*Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockade in Clinical B2 (T26NxMo) Prostate Cancer, (426002), TAP Pharmaceuticals Inc, $17,400 (adjustment).
Total: $33,705
Primary Total: $7,376
Multicenter Observational Study of Adverse Events in Coronary Bypass Patients Treated with Protamine Sulfate, (427987), Univ Hospital Consortium Technology Advancement, $375 (adjustment).
Neuromuscular Blockade in the Setting of Chronic Nicotine Exposure, (428937), Burroughs Wellcome Co, $7,000.
A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondanestron Versus Droperidol for the Prevention of Post Operative Nausea and Vomiting in Out- Patient Surgery, (433007), Glaxo Inc, $7,055 (adjustment).
*A Phase I/II, Open-Label, Rising-Dose, Safety and Feasibility Study of SNX-111 Administered Intrathecally to Terminally Ill Patients Suffering from Chronic Pain, (428718), Neurex, $8,329.
Battery for Health Improvement (BHI) Research Project, (428941), National Computer Systems Inc, $1.
*A Randomized Double Blind Placebo Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Post Operative Nausea and Vomiting in Out Patient Surgery, (427630), Glaxo Inc, $15,000 (adjustment).
*A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous Ondansetron for the Treatment of Postoperative Emesis in Pediatric Patients Undergoing Outpatient Surgery, (428456), Glaxo Inc, $3,000.
Total: $779,015
Primary Total: $779,015
*Model State Supported AHEC Programs, (428791), Univ of Louisville, $180,000.
*AHEC Special Initiatives, (427594), Univ of Louisville, $14,580 (adjustment).
*Kentucky Health Education and Training Center, (427586), Univ of Louisville, $166,000 (adjustment).
*Developing Telemedicine Capacity in Eastern Kentucky, (428588), Primary Health Care Bureau, $415,320.
*Area Health Education Center, (427616), Univ of Louisville, $3,115 (adjustment).
Total: $1,007,192
Primary Total: $871,746
*Predoctoral Research Training Program in Biopsychosocial Aspects of Breast Cancer, (428178), US Army Medical Research and Development Command, $216,246.
*Social Cognition Following Right Hemisphere Stroke, (426015), Neurological Communicative Disorders and Stroke, $106,846 (adjustment).
*Child Nutrition, Health and School Achievement, (428007), Child Health and Human Development, $28,600.
Research Training in Medical Behavioral Science, (427158), National Institute of Mental Health, $99,881 (adjustment).
Age Differences in Decision-Making Performance, (425488), National Institute on Aging, $88,573 (adjustment).
Stability and Precision of Human Performance During a Spaceflight Mission, (429201), National Aeronautics and Space Administration, $37,748.
*Behavioral Effects of Drugs of Abuse in Women, (428799), National Institute on Drug Abuse, $430,316.
Key Peer Opinion Leader/Gay Bar Outreach, (429000), Lexington Fayette County Health Department, $8,850.
Total: $3,267,498
Primary Total: $2,602,430
Isolation and Characterization of Gem-Like, A New Member of a Family of RAS-Related GTP-Binding Proteins, (433145), American Cancer Society, $14,000.
Glucose-Regulated Transcription in Yeast, (427046), National Science Fdtn, $90,000 (adjustment).
Molecular Genetic Analysis of Yeast Sphingolipids, (427637), National Institute of General Medical Sciences, $233,405 (adjustment).
Isolation of the Human Serine Palmitoyltransferase Gene, (427905), Council for Tobacco Research, $66,556.
Degradation of Opioid Peptides (change of grantee institution from Univ of TX SW Med Ctr at Dallas), (426433), National Institute on Drug Abuse, $277,473 (adjustment).
Choline Acetyltransferase, (427834), National Institute on Aging, $232,312 (adjustment).
State EPSCoR: KY Center for Structural Biology, (433096), KY Council on Public Higher Education, $198,000.
Summer Neuropeptide Conference, (428270), National Institute on Aging, $5,000.
NSF EPSCoR: KY Center for Structural Biology, (433095), National Science Fdtn, $263,000.
Summer Neuropeptide Conference, (428892), National Institute on Drug Abuse, $5,000.
Alzheimer's Disease Research Center: Project 3, (433087), National Institute on Aging, $114,488.
Fellowship for Eva Csuhai: Regulation of a Dynorphin B Converting Enzyme in Human Spinal Cord Cells, (428784), National Institute on Drug Abuse, $28,600.
Characterization of the Phoshosphingolipids, (428717), Eli Lilly and Co, $73,381.
*The Role of p40 in Yeast Cell Division Control, (428131), American Cancer Society, $90,000.
Endogenous Activators of Peroxisome Proliferation and Rodent Liver Tumors, (428177), American Cancer Society, $200,000.
Orphan Receptors of the Peroxisome Proliferator Family, (426812), National Institute Diabetes & Digestive & Kidney, $113,067 (adjustment).
Role of Cellular Stress Response in Nueral Tube Defects, (428617), March of Dimes Birth Defects Fdtn, $39,547.
Glycoconjugates of Leishmania, (427410), Allergy and Infectious Diseases, $241,190 (adjustment).
Molecular Bases of Leishmaniasis, (422845), Burroughs Wellcome Co, $10,000 (adjustment).
Glycosylation Mutants of Leishmania, (426355), Allergy and Infectious Diseases, $365,510 (adjustment).
*Calmodulin-Targeted Photoaffinity Cross-Linking Reagents, (432315), National Institute of General Medical Sciences, $76,638 (adjustment).
*Core C: Calicum Regulation in Brain Aging and Alzheimer's Disease, (432944), National Institute on Aging, $88,651.
*Role of Brain Specific Proteins in Nerve Function, (425294), Neurological Communicative Disorders and Stroke, $218,160 (adjustment).
Dolichol Phosphate Metabolism and Glycoprotein Synthesis, (426048), National Institute of General Medical Sciences, $218,229 (adjustment).
*Calmodulin-Targeted Photoaffinity Cross-Linking Reagents, (426359), National Institute of General Medical Sciences, $159,929 (adjustment).
The Role of NSF in Cellular Secretion: A Molecular Study, (428663), American Cancer Society, $185,000.
Total: $1,186,837
*Physiology and Pathophysiology of the Microcirculation, (432962), National Heart Lung and Blood Institute, $187,624.
*Physiology and Pathophysiology of the Microcirculation, (428403), National Heart Lung and Blood Institute, $948,236.
*Physiology and Pathophysiology of the Microcirculation, (432958), National Heart Lung and Blood Institute, $139,747.
*Physiology and Pathophysiology of the Microcirculation, (432960), National Heart Lung and Blood Institute, $145,759.
*Physiology and Pathophysiology of the Microcirculation, (432959), National Heart Lung and Blood Institute, $149,805.
*Physiology and Pathophysiology of the Microcirculation, (432957), National Heart Lung and Blood Institute, $70,775.
*Free Radicals, Apoptosis and Treatment of Decubitus Ulcers, (427704), Child Health and Human Development, $188,601 (adjustment).
*Research Supplement to Promote Recruitment of Individuals with Disabilities; Free Radicals, Apoptosis & Treatment of Decubitus Ulcers, (432953), Child Health and Human Development, $34,707.
*Analysis of the Effects of Extremely Low Frequency Electromagnetic Fields on Calcium "Spiking" in ROS 17/2.8 Cells, (427946), Electric Power Research Institute, $50,000 (adjustment).
Total: $1,686,298
Primary Total: $1,718,358
Cancer Information Service, (426943), National Cancer Institute, $808,210 (adjustment).
Central Highlands Appalachian Leadership Initiative on Cancer, (428488), National Cancer Institute, $277,770.
Sister to Sister, (428836), National Alliance of Breast Cancer Organizations, $10,000.
Kentucky Cancer Registry Program, (428555), Center for Disease Control, $320,485.
94-MISC-35SD-RS-25259 Protocol 2332 A Dose Ranging Efficacy Safety and Pharmacokinetic Study of Single Oral Doses of RS-25259 for Prevention of Nausea and Vomiting in Chemotherapy Naive Patients Receiving Highly Emetogenic, (428035), Syntex Research, $9,950 (adjustment).
*The Role of p40 in Yeast Cell Division Control, (428131), American Cancer Society, $90,000.
Regulation of Sicl Inhibition of Yeast Cdk Complexes, (428822), National Institute of General Medical Sciences, $171,551.
*Pre-Clinical Trail of CTB-1 )1F7) in SIV Infected Rhesus Macques, (428626), Immune Network Research Ltd, $30,500.
94-BRE-15SP: (Protocol #08341) A Phase III, Couble-Blind Randomized Study Evaluating the Safety and Efficacy of the Administration of SDZ ILS 969 [Recombinant Human Interleukim 6 (rhIL-6, E coli) Versus Placebo Following Cytoxan/, (428445), Sandoz Pharmaceuticals, $15,459.
*NSABP - A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer, (426051), Univ of Pittsburgh, $6,700 (adjustment).
94-BRE-16RP:(RP 56976-TAX264) Phase II Study of Docetaxel for Second Line Chemotherapy of Breast Cancer, (428635), Rhone Poulenc Pharmaceuticals, $9,681.
*Adjuvant Breast and Colorectal Cancer Therapy/NSABP, (428754), National Cancer Institute, $67,706.
*Immunotherapy and Gene Therapy of Cancer Program, (433066), Lucille P Markey Charitable Trust, $116,328.
Total: $126,160
Primary Total: $46,898
*Role of Neuropeptide CGRP in Vascular Response, (428174), National Heart Lung and Blood Institute, $79,262.
*Medical Applications of Apoptosis Inhibitors, (428917), LXR Biotechnology Inc, $2.
*Long-Term Organ Preservation for Transplantation, (426470), National Institute of General Medical Sciences, $46,896 (adjustment).
Total: $21,917
Primary Total: $20,040
*Metabolism, Perfusion, and Cognition in Vascular Dementia, (428638), Alzheimers Assoc, $30,000.
*Permeability of Human Gastrointestinal Mucosa to a New Radiopharmaceutical, Tc-99m-Q12, A Gastrointestinal Kinetic Study, (428600), Mallinckrodt Medical Inc, $20,040.
*Phenyl-butyl-nitrone (PBN) in Reperfusion Brain Injury Evaluated by Diffusion-Sensitized Magnetic Resonance Imaging, (428230), American Heart Assoc KY Affiliate, $10,721.
Total: $757,984
Primary Total: $730,498
Grants for Faculty Development in Family Medicine - Catalog of Federal Domestic Assistance 93.895, (427737), Health Professions Bureau, $282,028.
HRSA Predoctoral Training Grant, (427879), Health Professions Bureau, $152,910.
*Revised NLM Resource Grant Program, (428788), National Library of Medicine, $79,076.
*Assessment of the Kentucky Medicaid Program: Development of Clinical Guidelines, (428757), KY Cabinet for Human Resources, $34,166.
Rural-Urban Migration and Its Relationship to Rural HIV Health Service Delivery, (428675), Good Samaritan Fdtn, $5,176.
*Cooperative Agreement Program for Centers for Agricultural Research, Education and Disease and Injury Prevention, (433185), Center for Disease Control, $27,486.
Community Primary Care Program, (428212), Good Samaritan Fdtn, $58,500.
Community Primary Care Program, (432973), Good Samaritan Fdtn, $9,000.
*Catalog of Federal Domestic Assistance No. 93.979 Residency Training in Family Practice, (427923), Health Professions Bureau, $118,642.
Total: $4,855,068
Primary Total: $3,587,139
Human Thyroid Carcinoma Inhibition by Somatostatin, (427836), National Cancer Institute, $86,727 (adjustment).
A Six-week Cross-Over Study of the Effect of Beta-Glucan Versus Placebo on Serum Lipoproteins in Subjects with Primary Hypercholesterolemia, (428691), McNeil Specialty Products Company, $16,815.
A Placebo Controlled Comparative Trial of Cholestryamine Tablets and Their Combination with Pravastatin 20mg, (427219), Bristol Myers, $7,397 (adjustment).
Cholesterol Lowering Effects of Lactobacillus Acidophillus in Rats, (428834), MONA, $8,000.
Cholesterol Lowering Effects of Yogurt, (428707), MONA, $29,958.
A 52 Week Study of the Weight Loss Maintenance Effect of Orlistat in the Treatment of Obesity After a 24 Week Period of Weight Loss by Conventional Diet Therapy, (427414), Hoffmann La Roche Inc, $165,895 (adjustment).
A Randomized Double-Blind Placebo-Controlled Factorial Design Dose-Response Study of Temocapril HC1 (CS-622) Alone or in Combination with Hydrochlorothiazide in Patients with Mild to Moderate Essential Hypertension, (427753), Parexel International Co, $16,000 (adjustment).
A Multicenter, Randomized, Titrate-to Goal Comparison of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolemia (Type IIa & IIb), (428561), Merck and Company Inc, $10,600.
*Predoctoral Research Training Program in Biopsychosocial Aspects of Breast Cancer, (428178), US Army Medical Research and Development Command, $216,246.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433243), National Institute of Neurological Diseases & Stroke, $33,000.
*An Open-Label Study of the Pharmacokinetics of Venlafaxine in Extensive and Poor Metabolizers of Dextromethorphan, (428536), Wyeth Ayerst Research Inc, $72,444.
A Double-Blind, Parallel Group Evaluation of the Efficacy and Quality of Life Outcome of Salmeterol versus Placebo in Asthma Patients, (428305), Glaxo Inc, $6,600.
Residency Training in Primary Care Internal Medicine, (428013), Health Resources and Services Administration, $119,447.
*Premenstrual Asthma: A Sex Hormone-Beta2 Receptor Link, (428037), American College of Clinical Pharmacy, $10,000.
*Premenstrual Asthma A Sex Hormone Beta2 Ardrenoceptor Link, (428167), American Lung Assoc, $19,001.
A Randomized Double-Blind Study Evaluating the Safety and Efficacy of Intravenous Single Dose S-Adenosyl-L-Methionine 1, 4 Butanesulfate (SAMe SD4) on Methionine Metabolism Impairment and Intrahepatic Cholestasis in Patients with Cir,(428766), Knoll Pharmaceutical Company, $347,985.
*Alterations in Beta Adrenoceptor Function and Density During Acute Myocardial Infarction, (428272), American Heart Assoc KY Affiliate, $14,345.
A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study of the Chromic Administration of Vesnarinone in Heart Failure, (428811), Otsuka American Pharmaceutical Inc, $17,500.
Serum Amyloid A: Atherogenesis, (428295), National Institute on Aging, $166,642.
Function of Serum Amyloid A Protein, (427918), Council for Tobacco Research, $52,744.
Function of Serum Amyloid A Protein (SAA), (426430), National Institute Arthritis, Musculoskeletal & Skin, $179,825 (adjustment).
Biologic and Behavioral Correlates in Chronic Airflow Limitation, (428160), American Lung Assoc, $14,423.
*95-NHL-12ID: (Protocol 102-05) Pivotal Phase II Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients with Relapsed Low-Grade or Follicular B-Cell Lymphoma, (429034), IDEC Pharmaceuticals Co, $1.
*Anti-Idiotype Vaccine for Breast Cancer, (428687), National Cancer Institute, $158,396.
*Immunotherapy and Gene Therapy of Cancer Program, (428693), Lucille P Markey Charitable Trust, $450,000.
*Southwestern Oncology Group Cooperative Group Clinical Studies, (428678), National Cancer Institute, $75,214.
*Immunotherapy and Gene Therapy of Cancer Program, (433093), Lucille P Markey Charitable Trust, $8,000.
*New Therapeutic Approaches to Breast Cancer, (428722), National Cancer Institute, $131,722.
Evaluation of the Clinical & Cost Effectiveness of Therapy with Clarithromycin plus Omeprazole Compared to Omeprazole or Ranitidine for the Treatment of Patients with Duodenal Ulcer and Helicobacter pylori Infection, (428458), Abbott Laboratories, $3,789.
*Evaluation of the Role for Multidrug Resistance (MDR) Genes in Normal Human Lymphocyte Function, (428775), Pharmaceutical Manufacturers Assoc Fdtn, $12,500.
A Phase I Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of 935U83 After Multiple Dosing in Patients with HIV Infection, (428840), Burroughs Wellcome Co, $8,000.
A Randomized, Double-Blind, Multicenter Trial Accessing the Safety and Efficacy of a Single Intravenous Dose of CP-116,517 Compared with Cefotetan for the Prophylaxis of infection following Elective Colo-Rectal Surgery, (429047), National Medical Research Co, $1.
A Randomized, Double-Blind, Multicenter Trial Accessing the Safety and Efficacy of Intravenous Imipenem/Cilastatin Followed by Oral Amoxicilliam/Clavulanic Acid for the Treatment of Compicated Intra-Abdominal Infections, (429219), National Medical Research Co, $1.
*94-MISC-49FU: (Protocol 94-0-002) A Randomized, Double-Blind Comparative Trial of Ambisome (Liposomal Amphotericin B) Versus Amphotericin B in the Empiric Treatment of the Febrile Neutropenic Patient, (429108), Fujisawa Pharmaceuticals, $11,475.
A Multi-Center, Placebo Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety and Tolerance of: 1) 400mg Nevirapine in Combination with 500-600 mg/day of Zidovudine vs Zidovudine alone in Asymptomatic HIV-1, (427908), Boehringer Ingelheim, $17,632 (adjustment).
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of Less Than 300/mm3, (428251), Upjohn Company, $25,131 (adjustment).
A Double-Blind, Randomized, Dose-Response Study of Three Fixed Doses of Delavirdine Mesylate (U-90152S) in Combination with Zidovudine (ZDV) versus ZDV alone in HIV-1 Infected Individuals with CD4 Counts of 200-500/mm3, (428250), Upjohn Company, $10,770 (adjustment).
University of Cincinnati Aids Clinical Trials Unit, (428721), Univ of Cincinnati, $79,094.
Double Blind Randomized, Comparative, Multicenter Study of RP64206 (Sparflaxacin) vs Ofloxacin in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis, (427708), Rhone Poulenc Pharmaceuticals, $21,935 (adjustment).
A Multiclinic Open-Label Randomized Twenty-Four Week Study To Compare the Safety, Tolberability and Biological Activity of L-735, 524, Zidovudine and Didanosine Administered Concomitantly to L[0735, 524 Alone and Zidovudine and Didano,(428616), Merck and Company Inc, $14,438.
Treatment of Pseudomembranous Colitis by Standard Therapy and Saccharomyces Boulardii Compared with Standard Therapy and Placebo: A Double-Blind Study, (424339), Biocodex Inc, $84,314 (adjustment).
A Phase III Safety and Efficacy Trial of ABT-538 Plus Current Therapy vs Placebo Plus Current Therapy in HIV-Infected Patients, (428932), ClinTrials Research Inc, $1.
A Phase I/II Trial to Evaluate the Safety Tolerance and Phar Pharmacokinetics of 935U83 in Combination with VIDEX (didanosine) in Patients with HIV Infection, (428606), Burroughs Wellcome Co, $2.
Optional, Open Label, Extended Use Delavirdine Mesylate Treatment in Triple Combination for HIV-1 Patients Who Participated in Other Delavirdine Mesylate Protocols (M/331/0023), (428726), Upjohn Company, $40,500.
Safety and Immunogenicity of a Two-Dose Series of a Recombinant Hepatitis B Vaccine in Healthy Adults, (426908), Merck Sharp & Dohme Research Laboratories, $25,000 (adjustment).
Prospective, Randomized, (2:1) Non-Blinded Study of Intravenous Ciprofloxacin Monotherapy or Combination Therapy of Severe Infections (Multicenter), (427005), Miles Laboratories Inc, $11,250 (adjustment).
Azithromycin in the Treatment of Hospitalized Patients With Community-Acquired Pneumonia.A Multi-Center Open Comparative Trial Employing Cefuroxime as a Comparative Agent Protocol No. 93-CE33-06185, (427803), Pharmaco LSR, $63,120 (adjustment).
An Open-Label Randomized, Comparative, Multicenter Study of Clinafloxacin Versus a Ceftazideme-Based Regimen in the Treatment of Nosocomial Pnuemonia, (428914), Parke Davis, $3.
A Double-Blind Randomized, Comparative, Multicenter Study of CI-983 in the Treatment of Community-Acquired Bacterial Pneumonia, (425686), Parke Davis, $32,457 (adjustment).
A Randomized Blinded Comparative Study of Teicoplanin Versus Ceftriaxone in the Treatment of Moderate to Severe Skin and Soft Tissue Infeactions, (426446), Marion Merrell Dow Inc, $23,213 (adjustment).
A Randomized, Prospective, Comparative Study of the Efficacy of Cefoperazone/Sulbactam Plus Ciprofloxacin Versus Ceftazidime Plus Tobramycin in Febrile Neutropenic Patients, (424562), Pfizer Inc, $997 (adjustment).
*An Open Label Study of the Penetration of a Single Dose of Cefepime into the Cerebrospinal Fluid of Subjects with Non-Inflamed Meninges, (427804), Pharmaco LSR, $3,780 (adjustment).
Safety and Immunogenicity of a Two-Dose Regimen of RECOMBIVAX HB (20 or 40 mcg) in Healthy Adults Study 040-001, (427808), Merck and Company Inc, $126,200 (adjustment).
Safety and Immunogenicity in Healthy Adults of an Investigational Formulation of RECOMBIVAX HB (spi) Made From a New Recombinant Master Seed, (425965), Merck Sharp & Dohme Research Laboratories, $42,000 (adjustment).
Safety and Immunogenicity of a Two-Dose Regimen of RECOMBIVAX HB (20mcg) in Health Adults, (42), Merck and Company Inc, $81,600.
Safety and Immunogenicity of a Two-Dose Regimen of Recombivax HB in Older Adults, (427817), Merck and Company Inc, $43,000 (adjustment).
*A Nonrandomized, Historically Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous and/or Oral Levoflaxin in the Treatment of Chronic Osteomyelitis in Adults, (427035), R W Johnson Pharmaceutical Research Institute, $25,000 (adjustment).
*Multicenter Double-Blind Comparative Study of Intravenous MERREM (meropenum) and PRIMAXIN (imipenem cilastatin) For the Treatment of Intra-Abdominal Infections, (428290), ClinTrials Research Inc, $17,886 (adjustment).
Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events, (427034), Sterling Winthrop Research Institute, $9,200 (adjustment).
Thrombolysis and Thrombin Inhibition in Acute Myocardial Infarctrion (TIMI 9), (428744), Brigham and Womens Hospital, $1,100.
A Randomized Placebo Controlled Double Blind Parallel Study of Safety & Anti-Hypertensive Efficacy of Losartan Monothera py as Compared to HCTZ Monotherapy & to the Combination of Losartan & HCTZ in Patients w/Mild to Moderate Hypertension, (426123), Merck and Company Inc, $6,750 (adjustment).
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK-954), (425034), Merck Sharp & Dohme Research Laboratories, $3,762 (adjustment).
A Phase II, Double-Blind, Placebo Controlled Dose-Range and Short-Term Efficacy Study of UP 269-6 in Hypertensive Patients (GHBA_811), (428710), G H Besselaar Associates, $5,700.
The Role of Interleukin-8 in Alcoholic Liver Injury, (428159), National Institute on Alcohol Abuse and Alcoholism, $139,935.
Mechanisms of Interleukin-8 Induction in Alcoholic Liver Disease, (427907), Glaxo Inc, $38,000.
*Balloon Angioscope-Development of Aortic Balloon Angioscope and Endovascular Aortic Graft Delivery System, (428838), Baxter Healthcare Co, $30,000.
*Radiolabelling of Dosage Forms for Use in Pharyngeal and Esophageal Retention Scintigraphic Studies, (428871), Scintiprox Inc, $19,152.
*94-LUN-22SW (59075-103) A Phase II, Non-randomized, Open L, Multiple Dose Study Assessing the Efficacy and Safety of the Combination of Radiotherapy Plus Intravenously Administered Tirapazamine in Subjects with Stage IIIB..., (428734), Sanofi Winthrop Inc, $2.
*94-MISC-46GI(3004) A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with Moderately-High Emetogenic Chemotherapy, (428636), Glaxo Inc, $1,500.
*Drug Study - An Open-Label, Multicenter,Non-Comparative, Study of Topotecanas Single Agent, Second-Line Therapy in Patients with Small Cell Lung Cancer 94-LUN-20SKB (053), (428519), Smith Kline Beecham, $5,484 (adjustment).
*94-LUN-19SW (59075-201) Phase II Open Multicenter Study of Intravenously Administered Tirapazamine plus Cisplatin in Subjects with Previously Untreated Extensive Small Cell Lung Cancer, (428518), Sanofi Winthrop Inc, $3,717.
*94-MISC-44 MP (MP#43-92-P) Phase Trial of Intralesional CDDP-e Therapeutic Implant (MP#5010) in Patients with Primary or Metastatic Cancer of the Liver, (428520), Matrix Pharmaceutical Inc, $2.
*94-MISC-47GI(4002) A Randomized, Double-Blind Comparison of Single-Dose Intravenous Ondansetron Versus Single-Dose Intravenous Granisetron in the Prevention of Nausea Associated with High-Dose Cisplatin Chemotherapy, (428637), Glaxo Inc, $3,000.
*94-MISC-43IS: (IMCL CP-9401) Phase Ib/IIa Study of II-6m in Chemotherapy-Induced Thrombocytopenia in Patients with Advanced Malignancies, (428521), ImClone Systems, $3,717.
Studies on Indoor-Allergen Induced Pulmonary Inflammation, (427791), Center for Indoor Air Research, $82,881 (adjustment).
*Role of Milk versus Viral Proteins in the Pathogenesis of Type I Diabetes, (428975), National Dairy Council, $64,500.
Protocol E3A93 - Myeloma Project C: Immunology, (429144), Frontier Science and Technology Research Fdn Inc, $25,171.
Protocol E3A93 - Myeloma Project C: Immunology, (428582), AMC Cancer Research Center, $20,975.
*Structural Prerequisites for Amyloid Fibrillogenesis, (428443), National Institute on Aging, $156,331.
Vitamin D Receptor Mapping Intimate Sites of DNA Contact, (427862), National Institute Diabetes & Digestive & Kidney, $99,160 (adjustment).
CV-102-028 Comparison of the Safety and Efficacy of D-L Sotalol in Patients with Life Threatening VT-VF, (427772), Bristol Myers, $5,485 (adjustment).
Oral Bidisomide in Preventing Paroxysmol SVT and/or Atrial Fibrillation, (427827), G D Searle & Co, $29,850 (adjustment).
A Double-Blind, Randomized, Parallel, Sotalol-Controlled, Dose Confirmation Study to Investigate the Safety and Electrophysiologic Effects of MK-499 in Patients with Sustained Ventricular Tachyarrhythmias, (427854), Merck Sharp & Dohme Research Laboratories, $11,378 (adjustment).
Randomized Double Blind Placebo Controlled Evaluation of the Efficacy and Safety of Intravenous Administer Dofetilide in Subjects with Spontaneous or Induced Paraoxysmal Supraventricular Tachycardia, (428832), Pfizer Inc, $7,896.
*Brain Vasculature on Leukoaraiosis and Cardiac Surgery, (428584), Wake Forest Univ, $23,424.
Intravascular Slude and Angina, (428217), American Heart Assoc KY Affiliate, $12,844.
Comparison Between Continuous and Cyclical Long-Term Therapy with BMZ1.0955 in Established Osteopenia in Ovariohysterectomized Beagle Dogs, (425943), Boehringer Mannheim GmbH, $22,813 (adjustment).
*Project No.5A: Calicum Regulation in Brain Aging in Alzheimer's Disease, (433010), National Institute on Aging, $92,746.
22-Oxacalcitriol in Dogs with Experimental Renal Failure, (427071), Chugai Pharmaceutical Company, $97,680 (adjustment).
The Effects of 24-Epi-1, 25 Dihydroxyvitamin D2 in the Prevention and Reversal of Bone Loss Occurring After Cessation of Ovarian Function in Experimental Beagle Dogs, (427746), Elan Pharmaceuticals PLC, $229,500 (adjustment).
The Potential Value of Seven New Vitamin D Metabolites in the Prevention and Therapy of Osteoporosis Secondary to Cessation of Ovarian Function, (428169), Hoffmann La Roche Inc, $88,200.
Protocol # NUCAB3010 A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection Who Are Treatment Naive, (428898), Glaxo Inc, $1.
Protocol # NUCAB3011 A Placebo Controlled Study of Lamivudine and Intron A in Patients with Chronic Hepatitis B Infection who are Interferon Alpha Non-Responders, (428813), Glaxo Inc, $7,364.
*Evaluation of Delayed-Release Capsule Formulations for Colonic Delivery of Bisarodyl in Healthy Adults, (433022), Proctor & Gamble Company, $3,550.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433082), National Institute of Neurological Diseases & Stroke, $131,501.
Phase I Multiple Dose Study to Compare the Safety and Disposition of Sertraline and Desmethylsertraline in Normal Volunteers to Subjects with Hepatic Impairment, (426982), Pfizer Inc, $6,863 (adjustment).
A Mouse Model of Cancer Caused by Cyclin Dl/Bcl-1, (427889), Elsa U Pardee Fdtn, $20,045 (adjustment).
BCL-1: A Cyclin Proto-Oncogene, (428785), National Cancer Institute, $59,199.
Fellowship for J. Wroblewski: Analyses of D Type Cyclins with Monoclonal Antibodies, (428950), National Cancer Institute, $29,900.
A Phase 1, Single Dose Study to Determine the Safety and Pharmacoketics of Affinity Purified Ovine Anti-Tumor Necrosis Factor Alpha (Fab, Lyophilized), (429078), Therapeutic Antibodies, $1.
LY 307640 vs Ranitidine in the Treatment of Erosive or Ulcerative Gastroesophageal Reflux Disease, (428828), Pharamco LSR International Inc, $4,100.
A Multicenter, Randomized, Dougle-Blind, Placebo-Controlled, Evaluation of Healing And Relapse Rates Following Oral GR122 311X in Combination with Clarithromycin Compared with GR1223 11X, Clarithromycin, and Placebo in patients with Duodenal, (427826), Glaxo Inc, $9,820 (adjustment).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122 311X Compared with GR88502X, Ranitidine and Placebo in Patients With Benign Gastric Ulcer, (426134), Glaxo Inc, $33,715 (adjustment).
LY 307640 vs Placebo: Preventing Relapse in Erosive or Ulcerative Gastroesophageal Reflux Disease, (428830), Pharmaco LSR International Inc, $5,901.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of Healing and Relapse Rates Following Oral GR122 311X Compared with GR88502X, Ranitidine and Placebo in Patients with Duodenal Ulcer, (426141), Glaxo Inc, $4,240 (adjustment).
LY 307640 vs Ranitidine in the Treatment of Active Duodenal Ulcer Disease, (428829), Pharmaco LSR International Inc, $4,100.
LY 307640 vs Ranitidine in the Treatment of Active Gastric Ulcer Disease, (428831), Pharmaco LSR International Inc, $4,283.
Swallowing Impairment and Patterns of Esophageal Motility in Motor Neuron Disease, (428255), American College of Gastroenterology, $2,500.
*Prevention of Tobacco Use Among High-Risk Adolescents, (426107), National Cancer Institute, $10,071 (adjustment).
*Organization of Myocardial Electrical Activity During Ventricular Fibrillation and Probability of Defibrillation Success: Analysis of Orthogonal Surface Electrocardiograms, (428827), Whitaker Fdtn, $58,596.
Turberculosis Control, (427929), KY Department for Health Services, $10,000.
*Engineering Research Equipment: Digital Electronic Control System for ServoHydraulic Biomaterials Test System, (428246), National Science Fdtn, $25,760.
Kentucky Medical Review, (427603), KY Medical Review Organization, $12,600 (adjustment).
Blue Cross/Blue Sheild of Minnesota Research Contract, (428765), Blue Cross Blue Shield of Minnesota, $94,800.
Faculty Development in Internal Medicine, (428015), Health Resources and Services Administration, $108,212.
Three Dimensional Echocardiographic Assessment of Ventricular Remodeling Following Acute Myocardial Infarction, (427928), American Heart Assoc KY Affiliate, $17,535.
Dr. Peter Sapin - Pfizer Inc. Drug Study, (426919), Pfizer Inc, $2,825 (adjustment).
A Study of Occupational Therapy in Primary Care Elders, (428603), Retirement Research Fdtn, $66,690.
A Randomized, Multicenter, Three Month, Double-Blind, Pharmacokinetic, Safety and Tolerability Study of Sandimmune Neoral Soft Gelatin Capsules in Caparison to Sandimmune Soft Gelatin Capsules in Postoperative Primary Renal Transplant, (426950), Sandoz Pharmaceuticals, $16,173 (adjustment).
*Zinc B12 and Cognitive Decline in the Elderly, (428166), National Institute on Aging, $75,847.
Investigation of T10B9 or OKT3 Mediated in Situa Modulation of the CD3 Epitope of T Cells, (428478), Kidney Fdtn of Central KY, $10,000.
*The Mechanisms of Warfarin Resistance, (427989), American Heart Assoc KY Affiliate, $15,700.
*General Clinical Research Center, (428607), Research Resources, $490,668.
*General Clinical Research Center, Patient Care, (433016), Research Resources, $425,474.
*General Clinical Research Center: Nurses and Dieticians Salaries, (433015), Research Resources, $141,407.
*General Clinical Research Center - Clinical Associate Physician Peter Morris, MD, (433186), Research Resources, $57,023.
*Immunotherapy and Gene Therapy of Cancer Program, (433066), Lucille P Markey Charitable Trust, $116,328.
Total: $891,707
Primary Total: $881,636
*Development of Monoclonal Anti-Idiotype Antibodies for the Treatment of Breast Cancer, (428248), US Army Medical Research and Development Command, $129,771.
*95-MISC-55MP: (ZP-44389-01) Assessment of Toludine Blue Rinse as an Aid to Clinical Exam in the Identification of Recurrent or Second Primary Cancers of the Oral Cavity and in Biopsy Site Selection in Patients, (429109), Zila Pharmaceuticals, $500.
*A Multicenter Open Label, Maintenance, Study for the Relief of Xerostomia Associated with Radiation Induced Salivary Gland Hypofunction, (431845), MGI Pharma Inc, $2,452 (adjustment).
*New Therapeutic Approaches to Breast Cancer, (428722), National Cancer Institute, $131,722.
American Cancer Society Institutional Research Grant, (428150), American Cancer Society, $50,000.
*Immunotherapy and Gene Therapy of Cancer Program, (428693), Lucille P Markey Charitable Trust, $450,000.
*Anti-Idiotype Vaccine for Breast Cancer, (428687), National Cancer Institute, $158,396.
*95-NHL-12ID: (Protocol 102-05) Pivotal Phase II Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients with Relapsed Low-Grade or Follicular B-Cell Lymphoma, (429034), IDEC Pharmaceuticals Co, $1.
*Immunotherapy and Gene Therapy of Cancer Program, (433093), Lucille P Markey Charitable Trust, $8,000.
*Southwestern Oncology Group Cooperative Group Clinical Studies, (428678), National Cancer Institute, $75,214.
*94-MISC-49FU: (Protocol 94-0-002) A Randomized, Double-Blind Comparative Trial of Ambisome (Liposomal Amphotericin B) Versus Amphotericin B in the Empiric Treatment of the Febrile Neutropenic Patient, (429108), Fujisawa Pharmaceuticals, $11,475.
*94-LUN-19SW (59075-201) Phase II Open Multicenter Study of Intravenously Administered Tirapazamine plus Cisplatin in Subjects with Previously Untreated Extensive Small Cell Lung Cancer, (428518), Sanofi Winthrop Inc, $3,717.
*94-MISC-44 MP (MP#43-92-P) Phase Trial of Intralesional CDDP-e Therapeutic Implant (MP#5010) in Patients with Primary or Metastatic Cancer of the Liver, (428520), Matrix Pharmaceutical Inc, $2.
*94-MISC-43IS: (IMCL CP-9401) Phase Ib/IIa Study of II-6m in Chemotherapy-Induced Thrombocytopenia in Patients with Advanced Malignancies, (428521), ImClone Systems, $3,717.
*94-LUN-22SW (59075-103) A Phase II, Non-randomized, Open L, Multiple Dose Study Assessing the Efficacy and Safety of the Combination of Radiotherapy Plus Intravenously Administered Tirapazamine in Subjects with Stage IIIB..., (428734), Sanofi Winthrop Inc, $2.
*94-MISC-46GI(3004) A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with Moderately-High Emetogenic Chemotherapy, (428636), Glaxo Inc, $1,500.
*Drug Study - An Open-Label, Multicenter,Non-Comparative, Study of Topotecanas Single Agent, Second-Line Therapy in Patients with Small Cell Lung Cancer 94-LUN-20SKB (053), (428519), Smith Kline Beecham, $5,484 (adjustment).
A Prospective, Randomized, Multicentre Phase III Clinical Trial Comparing the Effects of PANOREX (17-1A Monoclonal Antibody) Injection Plus 5-Fluorouracil Plus Levamisole Versus 5-Fluorouracil Plus Levamisole in Patients with ..., (429200), Burroughs Wellcome Co., $2.
*94-MISC-47GI(4002) A Randomized, Double-Blind Comparison of Single-Dose Intravenous Ondansetron Versus Single-Dose Intravenous Granisetron in the Prevention of Nausea Associated with High-Dose Cisplatin Chemotherapy, (428637), Glaxo Inc, $3,000.
*Antibody Mediated Delivery and Expression of Genes, (428125), Council for Tobacco Research, $85,911.
M.P.Noland/R.J.Kryscio/R.S.Riggs/L.H.Linville/L.J.Perritt/T.C.Tucker
*Prevention of Tobacco Use Among High-Risk Adolescents, (426107), National Cancer Institute, $10,071 (adjustment).
*94-H&N-05AP: (Project #BZ-RM-1; Protocol #02-2.4) Benzydamine HCL in the Prophylactic Treatment of Prostradiation Oral Mucositis, (428690), Angelini Pharmaceuticals Inc Science & Technical, $3,717.
*NSABP - A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer, (426051), Univ of Pittsburgh, $6,700 (adjustment).
T.C.Tucker/G.H.Friedell
Data Based Intervention in Cancer Control, (428228), KY Cabinet for Human Resources, $7,208.
*Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockade in Clinical B2 (T26NxMo) Prostate Cancer, (426002), TAP Pharmaceuticals Inc, $17,400 (adjustment).
*SWOG Prostate Cancer Prevention Trial (PCPT), (427583), Southwest Oncology Group, $186,000 (adjustment).
*Immunotherapy and Gene Therapy of Cancer Program, (433066), Lucille P Markey Charitable Trust, $116,328.
Total: $30,500
Primary Total: $30,500
*Pre-Clinical Trail of CTB-1 )1F7) in SIV Infected Rhesus Macques, (428626), Immune Network Research Ltd, $30,500.
Total: $688,112
Primary Total: $688,112
*Implementation Grant: Preparing Physicians for the Future, (428289), Robert Wood Johnson Fdtn, $688,112.
Total: $4,334,552
Primary Total: $3,385,710
*Progressive Cholinergic Dysfunction in Aging Brain, (425614), National Institute on Aging, $134,359 (adjustment).
Regulation and Anti-Leukemia Responses of Syngeneic GVHD, (428019), Council for Tobacco Research, $50,000.
Immune Mechanisms and Murine Syngeneic GVHD, (425873), Allergy and Infectious Diseases, $109,399 (adjustment).
*Psychoneuroimmunology: Modulation of T-Cell Trafficking, (425522), National Institute of Mental Health, $101,574 (adjustment).
*Development of Monoclonal Anti-Idiotype Antibodies for the Treatment of Breast Cancer, (428248), US Army Medical Research and Development Command, $129,771.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433080), National Institute of Neurological Diseases & Stroke, $64,189.
Psychoneuroimmune Modulation of a Murine Model of AIDS, (428127), National Institute of Mental Health, $135,743.
*Mechanisms of Interstitial Pneumonitis in Murine AIDS, (428218), National Heart Lung and Blood Institute, $222,314.
*Clinical Studies on Monoclonal and Polyclonal Antibodies, (427776), Sigma Immunochemicals, $124,318 (adjustment).
A Genetic Approach to the Study of CAD, (426435), National Institute of General Medical Sciences, $162,715 (adjustment).
Acetyl-CoA Cleavage and Synthesis in Methanogens: Mechanistic, Enzymological, and Metabolic Studies, (428446), Department of Energy, $90,000.
Enzyme Catalyzed Insertion of Sulfur During Biotin Biosynthesis, (428821), National Science Fdtn, $93,115.
Glucocorticoid and PGE2 Modulation of T Cell Function, (428126), National Institute of Mental Health, $144,284.
*Peroxisomal Genes and Environmental Carcinogenesis, (426556), National Institute of Environmental Health Sciences, $167,239 (adjustment).
*Study of Radiation Induced Pulmonary Fibrosis, (428183), American Lung Assoc, $16,355.
*Carcinogen Induced Pulmonary Immunosuppression, (427698), National Institute of Environmental Health Sciences, $125,126 (adjustment).
Research Training in Cancer Etiology and Treatment, (428205), National Cancer Institute, $151,253.
*Antibody Mediated Delivery and Expression of Genes, (428125), Council for Tobacco Research, $85,911.
Immunoregulation by Corticotropin-Releasing Hormone, (425450), Neurological Communicative Disorders and Stroke, $7,674 (adjustment).
*Immunoregulation by Corticotropin-Releasing Hormone, (432878), Neurological Communicative Disorders and Stroke, $27,887.
Effects of Cellular Stress on Amyloid Precursor Protein (John R. Ciallella/pre-doc fellow), (428716), National Institute of Mental Health, $13,008.
*Modulation of Leukocyte Function in Preterm Neonates by Neuropeptides, (428532), Wyeth Pediatrics Neonatology Research Grants Prog, $3,500.
Iron Transport and Regulation in Yersinia Pestia, (427247), Allergy and Infectious Diseases, $189,184 (adjustment).
*Hemin Storage and Uptake in Yersinia Pestis, (432971), Allergy and Infectious Diseases, $23,718.
Hemin Storage and Uptake in Yersinia Pestis, (427569), Allergy and Infectious Diseases, $149,736 (adjustment).
Neuroimmunomodulation, (424586), Neurological Communicative Disorders and Stroke, $169,130 (adjustment).
Psychoneuroimmunology: Modulation of T-Cell Function, (428790), National Institute of Mental Health, $97,794.
Psychoneuroimmunology: Modulation of T-cell Function, (425115), National Institute of Mental Health, $162,279 (adjustment).
*Analysis of the Effects of Extremely Low Frequency Electromagnetic Fields on Calcium "Spiking" in ROS 17/2.8 Cells, (427946), Electric Power Research Institute, $50,000 (adjustment).
Establishment and Maintenance of Immunological Tolerance in Transgenic Mice, (428614), Council for Tobacco Research, $50,000.
Genetic Schemes to Clone Mammalian Transcription Factors, (425279), National Institute of General Medical Sciences, $116,148 (adjustment).
YopM Plaque Vaccine Componenet: Immunogenicity, Protectiveness, and Mode of Action, (432952), US Army Medical Research and Development Command, $252,910.
YopM Plaque Vaccine Componenet: Immunogenicity, Protectiveness, and Mode of Action, (428357), US Army Medical Research and Development Command, $660,318.
Plasmid pCD1-Encoded Virulence Determinants in Plague, (428658), Allergy and Infectious Diseases, $279,830.
A Transgenic Mouse Model for Tolerance in the Eye, (427634), National Eye Institute, $228,286 (adjustment).
Role of Ras Signaling Pathway in Brain Tumor Invasion, (428615), Council for Tobacco Research, $50,000.
Total: $881,287
Primary Total: $112,596
*Social Cognition Following Right Hemisphere Stroke, (426015), Neurological Communicative Disorders and Stroke, $106,846 (adjustment).
*Long-Term Organ Preservation for Transplantation, (426470), National Institute of General Medical Sciences, $46,896 (adjustment).
*An Open Label Study of the Penetration of a Single Dose of Cefepime into the Cerebrospinal Fluid of Subjects with Non-Inflamed Meninges, (427804), Pharmaco LSR, $3,780 (adjustment).
*A Phase II-III Prospective, Randomized, Placebo-Controlled Dose-Ranging Safety and Efficacy Study of Recombinant Human Ciliary Neurotrophic Factor (rHCNTF) in Patients with Amyotrophic Lateral Sclerosis, (426923), Regeneron Pharmaceuticals, $30,555 (adjustment).
*An Open Labl Safety Study of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metBDNF) Given by Daily Subcutaneous Injection to Patients with Amytrophic Lateral Sclerosis, (428847), AMGen, $9,601.
*Biomarkers of Brain Aging, (426995), National Institute on Aging, $222,256 (adjustment).
Stroke Trends and Distribution: United States, 1900-1990, (428628), National Institute of Neurological Diseases & Stroke, $86,875.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433082), National Institute of Neurological Diseases & Stroke, $131,501.
*Fellowship for Alex Tikhtman, M.D.: Calcium Metabolism, Cytoskeletal Proteins, and Ischemic Neuronal Necrosis, (427325), National Stroke Assoc, $15,000 (adjustment).
*Eicosanoids Mediate Effects of PAF in Cerebral Ischemia, (428858), Neurological Communicative Disorders and Stroke, $76,145.
*Antiphospholipid Antibodies and Stroke, (427702), Henry Ford Hospital for APASS Consortium, $737 (adjustment).
*Metabolism, Perfusion, and Cognition in Vascular
Dementia, (428638), Alzheimers Assoc, $30,000.
*Double-Blind, Randomized, Placebo-Controlled, Parallel- Group Trial of the Efficacy of Enlimomab (Anti-ICAM-1) Compared to Placebo Administered Within 6 hours of the Onset of Stroke Symptoms of Treatment of Acute Ischemic Stroke, (428573), Boehringer Ingelheim, $32,377.
*Alzheimer's Disease Cooperative Study Unit, (426468), Univ of California San Diego, $17,722 (adjustment).
*Selegiline (Deprenyl) Protocol, (426881), Univ of California San Diego, $31,625 (adjustment).
*Phenyl-butyl-nitrone (PBN) in Reperfusion Brain Injury Evaluated by Diffusion-Sensitized Magnetic Resonance Imaging, (428230), American Heart Assoc KY Affiliate, $10,721.
*Role of Brain Specific Proteins in Nerve Function, (425294), Neurological Communicative Disorders and Stroke, $218,160 (adjustment).
Total: $2,131,489
Primary Total: $2,018,437
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433080), National Institute of Neurological Diseases & Stroke, $64,189.
Ornithine Decarboxylase & Ischemic Brain Edema, (427524), Neurological Communicative Disorders and Stroke, $205,180 (adjustment).
Detection of Carotid Atherosclerotic Plaque Oxidation, (428196), American Heart Assoc KY Affiliate, $13,500.
WARSS Warfarin/Aspirin recurrent Stroke Study, (428773), Columbia Univ, $180,000.
Mechanisms of Brain Injury and Its Systemic Sequelae, (433079), National Institute of Neurological Diseases & Stroke, $175,783.
PFO in Cryptogeuic Stroke Study (PICSS), (42), Columbia Univ, $5,000.
Surgery for Spinal Cord Compression Due to Cancer, (426516), National Cancer Institute, $217,786 (adjustment).
*Controlled Delivery of Therapeutic Agents, (426896), Control Delivery Systems Inc, $106,052 (adjustment).
*Alpha 1 - Adrenergic Receptor in Traumatic Brain Injury (Revised Application -- See Shannon Award with same Title MIS #9208171341), (426934), Neurological Communicative Disorders and Stroke, $167,734 (adjustment).
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433077), National Institute of Neurological Diseases & Stroke, $136,332.
Role of TGF Beta in Human Glioma Cell Growth, Death, and Invasion, (433147), American Cancer Society, $7,000.
Asymptomatic Carotid Artery Stenosis Study, (427859), Wake Forest Univ, $7,205 (adjustment).
Mechanisms of Brain Injury and Its Systemic Sequelae, (433081), National Institute of Neurological Diseases & Stroke, $31,113.
Mechanisms of Brain Injury and Its Systemic Sequelae, (433078), National Institute of Neurological Diseases & Stroke, $184,352.
Prevent: Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial, (426443), Wake Forest Univ, $178,911 (adjustment).
ACAS-Asymptomatic Carotid Atherosclerosis Study, (433268), Wake Forest Univ, $2.
ACASS - Fixed Price Portion, (432774), Wake Forest Univ, $7,205 (adjustment).
ACAS-Asymptomatic Carotid Atherosclerosis Study, (429106), Wake Forest Univ, $37,296.
Mechanisms of Brain Injury and Its Systemic Sequelae, (428825), National Institute of Neurological Diseases & Stroke, $956,805.
Multicenter Dose Ranging Safety and Effectiveness Study of Peg-Superoxide Dismutase in Severe Head Injury, (426442), Sterling Winthrop Research Institute, $54,000 (adjustment).
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433076), National Institute of Neurological Diseases & Stroke, $79,012.
Factors Enhancing and Impairing Dopamine Grafts, (426813), Neurological Communicative Disorders and Stroke, $90,665 (adjustment).
Total: $1,175,644
Primary Total: $697,427
*Premenstrual Asthma: A Sex Hormone-Beta2 Receptor Link, (428037), American College of Clinical Pharmacy, $10,000.
*Premenstrual Asthma A Sex Hormone Beta2 Ardrenoceptor Link, (428167), American Lung Assoc, $19,001.
*Anti Tumorigenic Activity of Suramin Derivatives, (428173), American Cancer Society, $200,000.
Training Program in Reproductive Sciences, (427988), Child Health and Human Development, $65,002.
An Open, Multicenter, Phase II Study of Intravenous Topotecan, Given as Five Daily Doses Every 21 Days, In Advanced Epithelial Ovarian Cancer to Patients who have Failed One Prior Chemotherapy Regimen Containing Taxol, (427881), Smith Kline Beecham, $2,250 (adjustment).
Gynecologic Oncology Group, (424005), Gynecologic Oncology Group, $74,270 (adjustment).
An Open-Label, Multicenter, Randomized, Phase III Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Taxol in Women with Advanced Epithelial, (427880), Smith Kline Beecham, $2,250 (adjustment).
*Perinatal Recovery, Infant Development and Education (PRIDE) Evaluation, (429104), Bluegrass Regional Mental Health Mental Retardatio, $78,403.
*Behavioral Effects of Drugs of Abuse in Women, (428799), National Institute on Drug Abuse, $430,316.
*Apollo Genetics Contract, (427458), Apollo Genetics Inc, $7,900 (adjustment).
Improved Pregnancy Outcome Project, (427318), KY Cabinet for Human Resources, $4,305 (adjustment).
Improved Pregnancy Outcome Project, (428074), KY Cabinet for Human Resources, $65,105.
Balloon Probe for Fetal Monitoring, (429151), Corometrics Medical Systems Inc., $1.
*Antiestrogen Resistance: The Role of AESBS, (424849), National Cancer Institute, $205,841 (adjustment).
Environmental Chemicals: Relationship Between Mammary Carcinogenicity and Interactions with Estrogen Response Elements, (433146), American Cancer Society, $11,000.
*Training Program in Reproductive Sciences, (433099), Child Health and Human Development, $1,728.
Total: $404,532
Primary Total: $404,532
Application for RPB Unrestricted Development, (427699), Research to Prevent Blindness, $30,000 (adjustment).
Ischemic Optic Neuropathy Decompression Trial, (428026), National Eye Institute, $31,424 (adjustment).
*Eyelid Kinematics in Health and Disease, (428132), National Eye Institute, $116,886.
*Controlled Delivery of Therapeutic Agents, (426896), Control Delivery Systems Inc, $106,052 (adjustment).
Perimetric Mapping of Hyperacuity: Effects of Retinal Laser Scars, (428961), US Army Medical Research and Development Command, $120,168.
A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction with an Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Rentinitis, (428629), Syntex Research, $2.
Total: $50,760
*A Nonrandomized, Historically Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous and/or Oral Levoflaxin in the Treatment of Chronic Osteomyelitis in Adults, (427035), R W Johnson Pharmaceutical Research Institute, $25,000 (adjustment).
*Engineering Research Equipment: Digital Electronic Control System for ServoHydraulic Biomaterials Test System, (428246), National Science Fdtn, $25,760.
Total: $132,768
Primary Total: $132,768
Immunobiology of the Olfactory Mucosa, (426369), National Institute on Deafness & Other Communications, $152,314 (adjustment).
Total: $3,737,675
Primary Total: $1,128,695
Keratin Function in Epidermal Growth and Differentiation, (425688), National Institute Arthritis, Musculoskeletal & Skin, $121,368 (adjustment).
Keratin Protein Function in Epithelial Cell Growth and Differentiation, (427045), Council for Tobacco Research, $235 (adjustment).
Sensory Neuron Development in a Transgenic Mouse Model of Neurotrophin Deprivation, (428151), Dysautonomia Fdtn, $8,000.
Ovarian Tumor Bank (GOG-136), (428994), Gynecologic Oncology Group, $90,606.
Acquisition of Human Ovarian and Other Tissue Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Protocol #136, (432940), Gynecologic Oncology Group, $990 (adjustment).
*Clinical Studies on Monoclonal and Polyclonal Antibodies, (427776), Sigma Immunochemicals, $124,318 (adjustment).
*Effects of Overexpression of NGF in Transgenic Mice, (426996), Neurological Communicative Disorders and Stroke, $177,618 (adjustment).
*Effects of Overexpression of NGF in Transgenic Mice, (432980), Neurological Communicative Disorders and Stroke, $23,840 (adjustment).
*Polyamine Regulation and Arterial Intimal Hyperplasia, (426808), National Heart Lung and Blood Institute, $103,595 (adjustment).
*Peroxisomal Genes and Environmental Carcinogenesis, (426556), National Institute of Environmental Health Sciences, $167,239 (adjustment).
*Alzheimer's Disease Research Center: SDTC #1, (433242), National Institute on Aging, $68,433.
*Alzheimer's Disease Research Center: Pilot Study Funding, (432780), National Institute on Aging, $50,994 (adjustment).
*Alzheimer's Disease Research Center: SDTC #1, (432777), National Institute on Aging, $68,219 (adjustment).
*Neuropath Core, (432779), National Institute on Aging, $25 (adjustment).
*Alzheimer's Disease Research Center: SDTC #2, (432778), National Institute on Aging, $187 (adjustment).
*Alzheimer's Disease Research Center: Cinical Core C, (433085), National Institute on Aging, $581,330.
*Alzheimer's Disease Research Center: Neuopathalogy Core D, (433090), National Institute on Aging, $139,829.
*Alzheimer's Disease Research Center: SDTC #2, (433241), National Institute on Aging, $129,919.
*Alzheimer's Disease Research Center: Clinical Core, (432776), National Institute on Aging, $469 (adjustment).
*Alzheimer's Disease Research Center: Administrative Core, (428826), National Institute on Aging, $1,390,558.
*Ohio Valley Appalachia Regional Geriatric Education Center, (428329), Health Professions Bureau, $308,264.
*Alzheimer's Disease, Dental Amalgams and Mercury, (425673), National Institute on Aging, $152,600 (adjustment).
Mechanisms of DNA Repair in Active Genes, (424953), National Institute of General Medical Sciences, $112,598 (adjustment).
Characterization and Utilization of Opioid-like Hibernation Factors, (426269), US Army Medical Research and Development Command, $116,432 (adjustment).
*Antiestrogen Resistance: The Role of AESBS, (424849), National Cancer Institute, $205,841 (adjustment).
Chromosome 17 in the Early Stages of Ovarian Cancer, (427331), National Cancer Institute, $313,152 (adjustment).
Genetic Alterations in "Usual" and "Special Variant" Endometrial Carcinomas, (433148), American Cancer Society, $7,000.
Promoter Region Methylation and Gene Inactivation, (428170), Council for Tobacco Research, $75,000.
*The Spectrum of Mutation Induced by Ionizing Radiation, (426028), National Cancer Institute, $166,986 (adjustment).
*The Significance of Micrometastatic Prostate Cancer Cells, (428664), National Cancer Institute, $95,275.
Total: $2,355,878
Primary Total: $1,725,100
Role of Proteolysis in the Pathogenesis of BPD, (427846), National Heart Lung and Blood Institute, $208,971 (adjustment).
Cooperative Group Outreach Program - Childrens Cancer Group (CCG), (428916), National Childhood Cancer Fndtn, $5,600.
NIH Consortium Grant-Childrens Cancer Group (CCG), (428679), National Cancer Institute, $13,000.
Sickle Cell Newborn Screening Project, (428059), KY Cabinet for Human Resources, $7,000.
SERGG Publications, (428736), Emory Univ, $2,980.
Cabinet for Human Resources Subprogram Entitled Genetic Services, (428064), KY Cabinet for Human Resources, $149,000.
Cystic Fibrosis Center Grant, (428197), Cystic Fibrosis Fdtn, $27,430.
Short Title: "Exosurf Study" Long Title: " A Double-Blind, Randomized, Dose-Ranging Study of Exosurf Aerosol for Treatment of Cystic Fibrosis Lung Disease", (428758), Burroughs Wellcome Co, $4,400.
*Short Title: Nebulizer Systems Study for Mild Cystic Fibrosis, (428889), Genentech Inc, $1.
Nutritional Project for Infants and Children with PKU, Galactosemia, and Congenital Hypothyroidism, (428056), KY Cabinet for Human Resources, $106,759.
Genentech National Cooperative Growth Study Post Marketing Surveillance Program for Protropin/Somatrem and Nutropin/ Somatropin, (429197), Genentech Inc, $2,250.
*Modulation of Leukocyte Function in Preterm Neonates by Neuropeptides, (428532), Wyeth Pediatrics Neonatology Research Grants Prog, $3,500.
*Xenobiotic Transfer into Milk: A Diffusional Model, (426615), National Institute of General Medical Sciences, $327,278 (adjustment).
Infant Intensive Care Project, (428053), KY Cabinet for Human Resources, $548,509.
Developmental Evaluation Services, (428130), KY Cabinet for Human Resources, $161,500.
*IHDI-UAP-MCH Interdisciplinary Training & Leadership Development Program, (428474), Maternal and Child Health Bureau, $300,000.
*Regional Pediatrics Clinic Program, (428129), KY Cabinet for Human Resources, $154,400.
Young Parents Program, (428054), KY Cabinet for Human Resources, $297,000.
Young Parents Program, (427180), KY Cabinet for Human Resources, $6,300 (adjustment).
Harrison Elementary School-Based Clinic, (428752), Lexington Fayette County Health Department, $30,000.
Total: $2,797,960
Primary Total: $2,233,012
Project No.1: Calicum Regulation in Brain Aging in Alzheimer's Disease, (432949), National Institute on Aging, $154,553.
*Progressive Cholinergic Dysfunction in Aging Brain, (425614), National Institute on Aging, $134,359 (adjustment).
Project No.4: Calicum Regulation in Brain Aging in Alzheimer's Disease, (432946), National Institute on Aging, $129,137.
Age Influence on Ischemia Reperfusion in Brain, (425175), Univ of Oklahoma, $149,230 (adjustment).
Piracetam-mediated Prevention of Neuronal Membrane Damage Following Stimulation of Micochondrial Respiration, (429121), UCB Pharma, $14,900.
*Genetic Isolation of In Vivo and In Vitro PCP Responsiveness, (433005), National Institute on Drug Abuse, $50,743.
Drug Abuse Prevention: A Life Course Perspective-II, (432982), National Institute on Drug Abuse, $47,584.
*Scope Account for Genetic Isolation of In Vivo and In Vitro PCP Responsiveness, (432335), National Institute on Drug Abuse, $19,181 (adjustment).
*Genetic Isolation of In Vivo and In Vitro PCP Responsiveness, (426458), National Institute on Drug Abuse, $143,859 (adjustment).
Bioalkylation in Chemical Carcinogenesis, (426029), National Cancer Institute, $154,728 (adjustment).
Modulation of Cardiac L-Type Ca Channels, (427539), American Heart Assoc, $86,900 (adjustment).
Cholinergic Mechanisms of Analgesia, (427266), Neurological Communicative Disorders and Stroke, $132,686 (adjustment).
*Michelle Nehei/Neuropharmacology of Nicotinic Antinoception, (428501), National Institute of General Medical Sciences, $6,170.
PDGF Gene Transcription in Renal Epithelial Cells, (427606), National Institute Diabetes & Digestive & Kidney, $104,300 (adjustment).
Calcium Regulation in Brain Aging and Alzheimer's Disease: Project No. 3, (432947), National Institute on Aging, $82,902.
Calcium Regulation in Brain Aging and Alzheimer's Disease: Program Project 5C, (433045), National Institute on Aging, $93,614.
Hormonal Regulation of Calcium Currents in Aging and Neurotoxicity, (433026), National Institute on Aging, $136,342.
Parallel Model Systems of Aging-Dependent Neurodegeneration and Impaired Function, (428931), Bayer Pharmaceuticals, $1.
Calcium Regulation in Brain Aging and Alzheimer's Disease, (428252), National Institute on Aging, $946,636.
*Apollo Genetics Contract, (427458), Apollo Genetics Inc, $7,900 (adjustment).
Hippocampal Synaptic Structure - Physiology During Aging, (425161), National Institute on Aging, $109,876 (adjustment).
*Biomarkers of Brain Aging, (426995), National Institute on Aging, $222,256 (adjustment).
*Project No.5A: Calicum Regulation in Brain Aging in Alzheimer's Disease, (433010), National Institute on Aging, $92,746.
W.R.Markesbery
*Core B: Calicum Regulation in Brain Aging and Alzheimer's Disease, (432945), National Institute on Aging, $47,379.
M.P.Mattson
*Project No.2: Calicum Regulation in Brain Aging in Alzheimer's Disease, (432948), National Institute on Aging, $16,116.
*Alpha 1 - Adrenergic Receptor in Traumatic Brain Injury (Revised Application -- See Shannon Award with same Title MIS #9208171341), (426934), Neurological Communicative Disorders and Stroke, $167,734 (adjustment).
*Free Radicals, Apoptosis and Treatment of Decubitus Ulcers, (427704), Child Health and Human Development, $188,601 (adjustment).
Potential Convergence of AH Receptor/Arnt and MYC/MAX Signaling Pathways, (433149), American Cancer Society, $11,000.
*Core C: Calicum Regulation in Brain Aging and Alzheimer's Disease, (432944), National Institute on Aging, $88,651.
*Prolactin and Bile Secretory Function, (427863), National Institute Diabetes & Digestive & Kidney, $169,240 (adjustment).
Total: $259,376
Primary Total: $188,601
*Physiology and Pathophysiology of the Microcirculation, (432957), National Heart Lung and Blood Institute, $70,775.
*Free Radicals, Apoptosis and Treatment of Decubitus Ulcers, (427704), Child Health and Human Development, $188,601 (adjustment).
*Research Supplement to Promote Recruitment of Individuals with Disabilities; Free Radicals, Apoptosis & Treatment of Decubitus Ulcers, (432953), Child Health and Human Development, $34,707.
Total: $174,275
*Functional Anatomy of Limbic Neuroendocrine Circuits, (426571), National Institute of Mental Health, $109,775 (adjustment).
*Role of Milk versus Viral Proteins in the Pathogenesis of Type I Diabetes, (428975), National Dairy Council, $64,500.
Total: $4,675,584
Primary Total: $3,106,010
Sympathetic Nervous System Activity in Awake Dahl Rat, (428215), American Heart Assoc KY Affiliate, $13,754.
*Tutoring Program, (432987), National Institute of General Medical Sciences, $8,371.
*Come and See, (432989), National Institute of General Medical Sciences, $4,752.
*Physiology and Pathophysiology of the Microcirculation, (432962), National Heart Lung and Blood Institute, $187,624.
J.Diana/S.J.Lai-Fook/B.Hennig/D.R.Richardson/R.T.Dowell/R.Salcido
*Physiology and Pathophysiology of the Microcirculation, (428403), National Heart Lung and Blood Institute, $948,236.
*Influence of Tocolytic Agents, Ritodrine and MgSO4 on Placental/Ovarian Blood Flow, (428112), American Heart Assoc KY Affiliate, $14,499.
*Physiology and Pathophysiology of the Microcirculation, (432958), National Heart Lung and Blood Institute, $139,747.
NCRR Minority Initiative: K-12 Teachers and High School Students, (428587), Research Resources, $32,387.
Brainlink: A National Dissemination Plan, (429066), Baylor Univ Medical Center, $14,653.
HHMI Initiative Teacher Workshops, (432380), Howard Hughes Medical Institute, $4,000 (adjustment).
Program Project - Core, (433017), National Heart Lung and Blood Institute, $244,723.
*Bridges: Enhancing the Community College Baccalaureate Institution Connection, (428513), National Institute of General Medical Sciences, $468,830.
Respiratory Afferents and the Control of Breathing, (428608), National Heart Lung and Blood Institute, $774,048.
*Science Enrichment Program for Kentucky Appalachia, (426062), National Cancer Institute, $309,822 (adjustment).
Aging, the Suprachiasmatic Nucleus and Endocrine Rhythms, (428444), National Institute on Aging, $28,600.
*Physiology and Pathophysiology of the Microcirculation, (432960), National Heart Lung and Blood Institute, $145,759.
P-450 Arachidonate Metabolism and Loop Function, (427934), American Heart Assoc KY Affiliate, $14,800.
*Behavioral Effects of Drugs of Abuse in Women, (428799), National Institute on Drug Abuse, $430,316.
*Faculty Workshop, (432988), National Institute of General Medical Sciences, $3,998.
*Integrated Studies of Physiological Responses to Weightlessness and Hypotensive Challenges, (428771), Western KY Univ, $100,000.
*Physiology and Pathophysiology of the Microcirculation, (432961), National Heart Lung and Blood Institute, $164,913.
Project No. 3, (433018), National Heart Lung and Blood Institute, $190,987.
Mechanisms of Olfactory Integration, (427820), National Institute on Deafness & Other Communications, $89,139 (adjustment).
Mechanisms of Retinal Synaptic Plasticity, (425230), National Eye Institute, $124,876 (adjustment).
Mechanisms of Retinal Synaptic Plasticity, (433023), National Eye Institute, $23,652.
Mechanisms of Retinal Electrical Synaptic Plasticity, (428915), National Institute of Neurological Diseases & Stroke, $64,800.
Progesterone Receptor Gene Regulation in the Rat Ovary, (427821), Child Health and Human Development, $96,415 (adjustment).
Behavioral Ecology and Comparative Neurobiology, (428493), National Institute of Mental Health, $74,691.
Function of Cardiac Intrinsic Ganglia in Unanesthetized Dog, (427930), American Heart Assoc, $39,930.
*Physiology and Pathophysiology of the Microcirculation, (432959), National Heart Lung and Blood Institute, $149,805.
*Physiology and Pathophysiology of the Microcirculation, (432957), National Heart Lung and Blood Institute, $70,775.
*Characterization and Quantification of Grafted Cell Survival, (427728), Theracell Inc, $50,723 (adjustment).
*Information Core, (432775), National Institute on Aging, $435 (adjustment).
*Alzheimer's Disease Research Center: Information Core E, (433089), National Institute on Aging, $86,803.
Neuroendocrine and Neurochemical Function During Aging, (427315), National Institute on Aging, $586,059 (adjustment).
Training Program in the Molecular and Cellular Basis of Brain Aging, (428586), National Institute on Aging, $186,451.
Neuroendocrine and Neurochemical Function during Aging, (433253), National Institute on Aging, $305,450.
Neuroendocrine and Neurochemical Function During Aging, (432950), National Institute on Aging, $19,841.
Alzheimer's Disease Research Center: Pilot 1, (433086), National Institute on Aging, $29,800.
Training Program in the Molecular and Cellular Basis of Brain Aging, (428894), National Institute on Aging, $186,755.
Total: $2,935,752
Primary Total: $1,894,535
*NIEHS Hazardous Waste Worker Training, (428509), Univ of Cincinnati, $140,000.
Preventive Medicine Residency, (427916), Health Resources and Services Administration, $108,836.
Technical Assistance to KWRRI, (433059), KY Natural Resources Environmental Protection Cab, $43,802.
E-Systems/Serv-Air Medical Program, (428591), E Systems Inc, $33,600.
National Aids Education and Training Center, (429052), Wayne State Univ, $102,000.
*Cooperative Agreement Program for Centers for Agricultural Research, Education and Disease and Injury Prevention, (433094), Center for Disease Control, $4,849.
Kentucky Labor Cabinet Agreement, (428510), KY Department of Labor, $10,000.
Kentucky Occupational Medicine Residency Program, (427998), Center for Disease Control, $98,411.
*NIEHS Hazardous Waste Worker Training, (427455), Univ of Cincinnati, $30,000 (adjustment).
Kentucky Natural Resources and Environmental Protection Cabinet, (427585), KY Department of Environmental Protection, $5,000 (adjustment).
*Use of DNA Adducts as Surrogate Endpoint Biomarkers in Determining the Efficacy and Potential Mechanisms for Various Chemopreventive Agents, (432994), National Cancer Institute, $152,736.
*Glenda Spencer/Detection of DNA Adducts in Various Human Tissues Including: Urinary Bladder Prostate and Gastro Intestinal, (428368), National Institute of Environmental Health Sciences, $14,157.
Mechanisms of Benz(a)Pyrene Carcinogenesis, (427724), Research Fdtn of State Univ of New York, $79,471 (adjustment).
*Use of DNA Adducts as Surrogate Endpoint Biomarkers in Determining the Efficacy and Potential Mechanisms for Various Chemopreventive Agents, (428525), National Cancer Institute, $429,017.
*Cooperative Agreement Program for Centers for Agricultural Research, Education and Disease and Injury Prevention, (433024), Center for Disease Control, $45,004.
*Cooperative Agreement Program for Centers for Agricultural Research, Education and Disease and Injury Prevention, (433185), Center for Disease Control, $27,486.
Farm Family Health Hazard and Surveillance Project, (428451), Center for Disease Control, $212,826.
Cooperative Agreement Program for Centers for Agricultural Research, Education and Disease and Injury Prevention, (428470), Center for Disease Control, $460,000.
*Empowering Farm Women to Reduce Hazards to Family Health and Safety on the Farm, (428304), W K Kellogg Fdtn, $140,469.
*Equestrian Safety Project, (428596), KY Department for Health Services, $6,150.
*Mechanisms of Carcinogenesis: Halogenated Biphenyls, (426925), National Cancer Institute, $132,907 (adjustment).
*The Epidemiology of Aging and Alzheimer's Disease, (427730), National Institute on Aging, $66,004 (adjustment).
*Independent and Dependent Life in the Elderly, (424729), National Institute on Aging, $784,347 (adjustment).
Enhance Communications and Develop National Avenue for the Dissemination of the Latest Clinical Information of HIV Disease, (428548), Health Resources and Services Administration, $24,900.
Systematic Collection of Information/Data from the AETC Network, (428549), Health Resources and Services Administration, $13,855.
*Farm Family Health Hazard and Surveillance Project, (432986), National Institute of Occupational Safety and Health, $133,278.
Farm Family Health Hazard and Surveillance Project, (432963), National Institute of Occupational Safety and Health, $50,886.
Total: $438,322
Primary Total: $52,038
*Revised NLM Resource Grant Program, (428788), National Library of Medicine, $79,076.
*Assessment of the Kentucky Medicaid Program: Development of Clinical Guidelines, (428757), KY Cabinet for Human Resources, $34,166.
*Catalog of Federal Domestic Assistance No. 93.979 Residency Training in Family Practice, (427923), Health Professions Bureau, $118,642.
Computer-Based Assessment of the American Board of Family Practice, (428649), Rovinelli Assoc Inc, $52,038.
*Regional Pediatrics Clinic Program, (428129), KY Cabinet for Human Resources, $154,400.
Total: $2,417,395
Primary Total: $182,688
*A Multicenter, Open-Label, Study of the Safety and Tolerability of Metrifonate (BAY A 9826) in Patients with Probable Alzheimer's Disease, (428749), Miles Laboratories Inc, $27,863.
*Evaluation of Student Assistance Programs: Phase III ..., (433047), KY Cabinet for Human Resources, $54,282.
*Evaluation of Student Assistance Programs: Phase III ..., (433048), KY Cabinet for Human Resources, $55,100.
*Evaluation of Student Assistance Programs: Phase III Scope:(2) DUI Program and (3) Youth Access to Tobacco in KY: Feasibility of Implementing Synar, (428060), KY Cabinet for Human Resources, $193,381.
*Perinatal Recovery, Infant Development and Education (PRIDE) Evaluation, (429104), Bluegrass Regional Mental Health Mental Retardatio, $78,403.
Physician Scientist Research Career Development Award, (427413), American Academy of Child & Adolescent Psychiatry, $82,688 (adjustment).
Psychiatry Research and Program Development, (424942), KY Cabinet for Human Resources, $100,000 (adjustment).
Perinatal Recovery Infant Development and Education Program (PRIDE), (433256), Bluegrass Regional Mental Health Mental Retardatio, $20,000.
*Evaluation of Student Assistance Programs: Phase III ..., (432942), KY Cabinet for Human Resources, $19,550.
*Combination of Three Programs (1) Needs Assessment (2) Follow up and Data Systems and (3) Women and Substance Abuse, (428067), KY Cabinet for Human Resources, $774,388.
*Institute on Women and Substance Abuse, (432912), KY Cabinet for Human Resources, $233,777.
*Follow Up and Data Systems Treatment Project, (432913), KY Cabinet for Human Resources, $178,057.
*Aids Prevention for Drug Injectors in KY, (429028), National Institute on Drug Abuse, $386,393.
*State Demand and Needs Assessment Studies Alcohol and Other Drugs, (432914), KY Cabinet for Human Resources, $362,554.
*Aids Prevention for Drug Injectors in Kentucky, (427968), National Institute on Drug Abuse, $27,551 (adjustment).
*CSAT Technical Assistance, (428805), Macro International, $5,490.
*Rural CAP Contract, (428778), Rural Alaska Community Action Program Inc, $25,000.
*Histamine Diet and Food Intake, (428407), Department of Agriculture, $110,000.
*Kentucky Health Education and Training Center, (427586), Univ of Louisville, $166,000 (adjustment).
*AHEC Special Initiatives, (427594), Univ of Louisville, $14,580 (adjustment).
*Developing Telemedicine Capacity in Eastern Kentucky, (428588), Primary Health Care Bureau, $415,320.
*Model State Supported AHEC Programs, (428791), Univ of Louisville, $180,000.
*Area Health Education Center, (427616), Univ of Louisville, $3,115 (adjustment).
Total: $334,234
Primary Total: $164,281
*Study of Radiation Induced Pulmonary Fibrosis, (428183), American Lung Assoc, $16,355.
*Carcinogen Induced Pulmonary Immunosuppression, (427698), National Institute of Environmental Health Sciences, $125,126 (adjustment).
*94-H&N-05AP: (Project #BZ-RM-1; Protocol #02-2.4) Benzydamine HCL in the Prophylactic Treatment of Prostradiation Oral Mucositis, (428690), Angelini Pharmaceuticals Inc Science & Technical, $3,717.
*The Spectrum of Mutation Induced by Ionizing Radiation, (426028), National Cancer Institute, $166,986 (adjustment).
*The Combined Effect of UCN-01 and Radiation on Various Tumors, (428962), Kyowa Hakko Kogyo Co Ltd, $22,800.
Total: $1,726,403
Primary Total: $1,585,934
Grants for Graduate Training in Family Medicine, (428014), Health Professions Bureau, $61,992.
Kentucky HomePlace, (428569), KY Cabinet for Human Resources, $1,000,000.
*Empowering Farm Women to Reduce Hazards to Family Health and Safety on the Farm, (428304), W K Kellogg Fdtn, $140,469.
Kentucky Commonwealth Office of Rural Health, (428476), Primary Health Care Bureau, $65,445.
Cooperative Agreement for Primary Care, (428835), KY Cabinet for Human Resources, $8,068.
Kentucky Rural Community Scholarship Program, (428535), KY Department for Health Services, $70,679.
Cooperative Agreement for Primary Care, (428253), KY Cabinet for Human Resources, $34,000.
EMS/Trauma Systems Planning, (428254), KY Cabinet for Human Resources, $37,100.
*Practice Sights: State Primary Care Strategies for KY, (428442), Robert Wood Johnson Fdtn, $308,650.
Total: $358,422
Primary Total: $280,633
*Role of Neuropeptide CGRP in Vascular Response, (428174), National Heart Lung and Blood Institute, $79,262.
*Polyamine Regulation and Arterial Intimal Hyperplasia, (426808), National Heart Lung and Blood Institute, $103,595 (adjustment).
*Multicenter Double-Blind Comparative Study of Intravenous MERREM (meropenum) and PRIMAXIN (imipenem cilastatin) For the Treatment of Intra-Abdominal Infections, (428290), ClinTrials Research Inc, $17,886 (adjustment).
*Balloon Angioscope-Development of Aortic Balloon Angioscope and Endovascular Aortic Graft Delivery System, (428838), Baxter Healthcare Co, $30,000.
*Pivotal Study of Human MAB-T88 in Patients with Gram Negative Sepsis, (425147), Cetus Co, $54,000 (adjustment).
*A Double-Blind Randomized Placebo-Controlled Dose-Response Study of Inhaled Nitric Oxide (OHM-11771) in the Treatment of Acute Respiratory Distress Syndrome (ARDS), (428455), Ohmeda Pharmaceuticals, $17,649.
*Phase II Multicenter, Double-Blind, Randomized, Placebo- Controlled, Dose-Finding, Safety, and Tolerability Trial of Recombinant Human Insulin-Like Growth Factor (rhIGF-1) in Patients with Acute Kidney Failure, (428652), Chiron Therapeutics, $14,210.
Market Release Study of the Baxter Reinforced PTFE Vascular Graft, (428798), Baxter Healthcare Co, $2,000.
*A Study of IL-1 Inducible Genes in Human Melanoma Cells (this is a transfer grant), (426146), National Cancer Institute, $115,681 (adjustment).
*Adjuvant Breast and Colorectal Cancer Therapy/NSABP, (428754), National Cancer Institute, $67,706.
Breast Cancer Education Initiatives, (428468), National Cancer Institute, $65,776.
Total: $439,647
Primary Total: $316,620
*A Study of IL-1 Inducible Genes in Human Melanoma Cells (this is a transfer grant), (426146), National Cancer Institute, $115,681 (adjustment).
Characterization of Apoptosis-Specific Genes in Prostate Carcinoma Cells, (428609), Council for Tobacco Research, $70,000.
94-GU-32PD: (Protocol 1003-01) A Double-Blind, Randomized, Phase 3, Multicenter Study of Suramin Versus Placebo in the Treatment of Patients with Metastatic, Hormone-Refractory Prostate Carcinoma (Stage D2), (429033), Warner Lambert Company, $12,000.
Data Coordinator for Urology Protocols, (429038), Southwest Oncology Group, $23,664.
*SWOG Prostate Cancer Prevention Trial (PCPT), (427583), Southwest Oncology Group, $186,000 (adjustment).
*The Significance of Micrometastatic Prostate Cancer Cells, (428664), National Cancer Institute, $95,275.
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6-30-03